16 results about "Immunologic preparation" patented technology

The present disclosure provides an anti-tetanus toxin neutralizing antibody as a new generation of tetanus passive immunization preparation. The antibody can be fully human, which can specifically bind to full-length tetanus toxin and its AB fragment, has high affinity, high specificity, small toxic side effects, avoids the problems of large adverse reactions and short half-life of animal-derived monoclonal antibodies, and is prepared in large quantities by mammalian cells, and has clear and stable components.

The invention relates to a DC cell for expressing a multispecific T cell adapter, a preparation method and application thereof, and an immune preparation containing the DC cell. The preparation method comprises the following steps: preparing a nucleic acid construct for coding a multispecific T cell adapter, the multispecific T cell adapter comprising a first antigen binding domain for specifically binding with CD3 on the surface of a T cell to activate the T cell, and a second antigen binding domain for specifically binding with B7H3 on the surface of a tumor cell, and an immunomodulatory molecule interleukin-2, i.e., a third binding domain, capable of binding to an IL-2 receptor on the surface of an immune cell; and transferring the nucleic acid construct as an exogenous nucleic acid into the DC cell to obtain the DC cell for expressing the multispecific T cell adaptor. The DC cell expressing the multispecific T cell adapter can assist a human immune system in better and more targeted killing of tumor cells.

The invention relates to an anti-immunological rejection FK506 (at) ZIF-8 / HTCC ophthalmic gel and a preparation method thereof, FK506 and a zeolite imidazole skeleton (ZIF-8) are combined to prepare FK506 loaded nanoparticles (FK506 (at) ZIF-8), and quaternized chitosan is innovatively used as a sol of the FK506 (at) ZIF-8 to prepare the ophthalmic gel for use. The problems that a novel potent immune preparation tacrolimus administration mode is short in drug retention time, fast in metabolism, poor in cornea permeability and insoluble in water, and consequently the bioavailability of the FK506 eye drops is low are solved. Compared with an FK506 direct administration mode, the administration mode of the novel nanoparticle drug-loaded ophthalmic gel is higher in drug utilization rate, has a treatment effect on corneal transplantation immunological rejection, and delays the occurrence and development of transplantation rejection.

The invention belongs to the field of immune drug development. The invention particularly relates to a T cell in-vitro proliferation culture method and application thereof. By changing the coating amount of the anti-CD3e antibody and the concentration combination of beta-mercaptoethanol with different concentrations in the T cell culture medium provided by the invention, the effect of accurately controlling the background proliferation of the T cells is achieved; the kit prepared from the related raw materials of the method is used for detecting the activity of the immune preparation.

The application discloses a recombinant bacillus subtilis of surface display of a fusion protein of Edwardsiella tarda outer membrane protein OmpA and Vibrio cholerae enterotoxin CTB, a construction method and application. A homologous double cross recombinant of coding genes of OmpA and CTB is carried out into a genome of the bacillus subtilis 168 by taking the spore coat protein CotY as an anchor point, so that the recombinant bacillus subtilis capable of stably inheriting in the bacillus subtilis and displaying the Edwardsiella tarda outer membrane protein OmpA and the Vibrio cholerae enterotoxin CTB on a spore surface is obtained. After fish and mammals orally immunize the bacillus subtilis, the survival time and survival rate of the fish and mammals after infection of the Edwardsiella tarda are obviously improved. The recombinant bacillus subtilis is used as an oral vaccine type micro-ecological immunization preparation for preventing and treating the Edwardsiella tarda infection of the fish and mammals, so that the immunization procedure is obviously simplified, the immunization stress is reduced, the labor cost is saved, the effective concentration in the intestinal tract is ensured, and the specific immune response of the body is induced.

The invention relates to the technical field of immune preparations, in particular to application of Forskolin or pharmaceutically acceptable salt thereof in preparation of a vaccine immunopotentiator. Aiming at the defects of vaccine immunomodulators in the prior art, the invention provides a novel method for enhancing the immune effect of a vaccine by using a natural plant extract Forskolin (as an adenylate cyclase activator), the Forskolin can promote high expression of CXCR4 by plasma cells to obviously enhance the homing ability, the residence ability and the service life of the plasma cells, so that the immune effect of the vaccine is enhanced. Therefore, the long-term immune response of the antibody is improved. The Forskolin directly targets the effector cytoplasm cells immunized by the vaccine, so that the potential safety hazard of the traditional technology is avoided, and meanwhile, more lasting and stable immune protection is provided.

Provided are an anti-tetanus toxin neutralizing antibody and the use thereof as a new-generation tetanus passive immunological preparation. The antibody can be a fully human antibody, has the characteristics of a high affinity, a high specificity, and few toxic side effects, and avoids the problems of strong adverse reactions and a short half-life of animal-derived monoclonal antibodies. Moreover, the antibody can be prepared on a large scale using mammalian cells, and has a clear and stable composition. On the basis of clinical requirements, the exploration and development of an anti-tetanus toxin neutralizing fully-human antibody as a new-generation tetanus passive immunological preparation has great medical value.

The invention relates to the technical field of biological medicine, and discloses an application of astragalus polysaccharide extracted by optimizing an alcohol precipitation process as an H3N2 influenza vaccine adjuvant, the application comprises the following steps: mixing the astragalus polysaccharide and an H3N2 influenza vaccine to prepare an immune preparation, extracting the astragalus polysaccharide by an ethanol precipitation method with the final concentration of 80%, the yield of the astragalus polysaccharide is 7.0-9.0% (based on the dry weight of raw materials), and the content of the astragalus polysaccharide in the H3N2 influenza vaccine adjuvant is 1-5%. In addition, the immune preparation can be used for remarkably improving the serum H3N2HI titer (Plt; 0.05) of the method. According to the application of the astragalus polysaccharide extracted by the optimized alcohol precipitation process as the H3N2 influenza vaccine adjuvant, the yield is 7.0-9.0% through the optimized alcohol precipitation process such as a precise extraction process and an ethanol precipitation method with the final concentration of 80%, and the prepared astragalus polysaccharide remarkably improves the serum H3N2HI titer (Plt; 0.05), the early-stage enhancement of the immune effect of the vaccine is assisted, the immune enhancement effect is synergistically exerted by scientifically matching the vaccine and combining 800 [mu] g of each animal with 15 [mu] g of H3N2 vaccine for each animal by determining the additive amount, and the effectiveness of matching of the adjuvant and the vaccine is guaranteed.

This invention discloses a recombinant protein for the prevention of Klebsiella pneumoniae, its gene, and its applications. The recombinant protein includes specific antigenic epitopes of Klebsiella pneumoniae OmpA protein and / or OmpX protein. The amino acid sequences of the specific antigenic epitopes of the Klebsiella pneumoniae OmpA protein are shown in SEQ ID NO.1, and the amino acid sequences of the specific antigenic epitopes of the Klebsiella pneumoniae OmpX protein are shown in SEQ ID NO.2. The recombinant protein can be efficiently expressed in a prokaryotic system and, after purification and refolding, exhibits good immunogenicity. Animal experiments show that this recombinant protein can induce high-titer specific antibodies and cellular immune responses in mice and provides significant protection against lethal doses of Klebsiella pneumoniae challenge. The single-component proteins KP-A and KP-X showed higher protection rates in the challenge experiment. The recombinant protein provided by this invention can be used to prepare vaccines or immunizing agents for the prevention and / or treatment of Klebsiella pneumoniae infection.

The invention relates to the technical field of medical instruments, and discloses glioma postoperative immune combined oncolytic virus implantation equipment which comprises a release pipeline, the left side face of the release pipeline is communicated with an immune preparation storage bin, and the right side face of the release pipeline is communicated with an oncolytic virus storage bin. An extrusion fitting device and an elastic fixing device are respectively arranged on the outer surfaces of the immune preparation storage bin and the oncolytic virus storage bin. According to the glioma postoperative immune combined oncolytic virus implantation equipment, an extrusion fitting device is arranged, an electric push rod is used for driving a movable rack plate to move and driving a rotating gear and a stable shaft to rotate, then a swing plate and a fitting column swing and fit towards the wall of an operation cavity, the fitting angle and force can be adjusted according to the actual shape of the operation cavity, and the operation efficiency is improved. The problem that existing equipment is difficult to adapt to form changes of an operation cavity is solved, it is ensured that a medicine release face makes full contact with the operation cavity wall, and medicine absorption efficiency is improved.

The present invention discloses a Ferritin L gene of Hefang Crucian Carp and its recombinant protein. The nucleotide sequence of the Ferritin L gene of Hefang Crucian Carp is shown as SEQ ID NO: 1, and the amino acid sequence of the recombinant protein is shown as SEQ ID NO: 2. The discovery of the Ferritin L gene of Hefang Crucian Carp not only enriches the gene library of Hefang Crucian Carp, but also can be used to prepare recombinant proteins. Experiments have shown that the recombinant protein can inhibit the growth activity of Aeromonas hydrophila, providing a new practical basis for the physiological immunity research of Hefang Crucian Carp. The present invention also discloses a preparation method of the Ferritin L recombinant protein of Hefang Crucian Carp, the application of the Ferritin L recombinant protein of Hefang Crucian Carp in the fields of inhibiting the growth of Aeromonas hydrophila, immune preparations or feed additives for aquatic animals, and primers for amplifying the Ferritin L gene of Hefang Crucian Carp.

The application discloses a nucleic acid delivery carrier, a delivery system and application thereof. The nucleic acid delivery carrier is constructed by inserting a CpG sequence into a multi-cloning site of a eukaryotic expression carrier, and the nucleic acid delivery system is constructed by the delivery carrier and probiotics. Based on the delivery carrier, the nucleic acid to be delivered is inserted into the delivery carrier and then transformed into probiotics to construct a recombinant bacteria preparation. The nucleic acid to be delivered can be delivered into the body by orally taking or injecting the recombinant bacteria preparation, which overcomes the deficiency that the nucleic acid is difficult to be efficiently delivered into the body by only using the recombinant expression carrier to transform the recombinant bacteria. The nucleic acid delivery carrier or the delivery system can be used to deliver the nucleic acid with therapeutic or immune effect into the body, and the nucleic acid delivery carrier or the delivery system can be used to prepare a medicine or an immune preparation for treating diseases by delivering the nucleic acid, and has wide application.

The invention belongs to the technical field of molecular biology, and relates to a recombinant protein of a serine protease inhibitor EsKPI-1 containing a Kazal structural domain of Eriocheir sinensis as well as a preparation method and application of the recombinant protein. The amino acid sequence of the recombinant protein rEsKPI-1 is shown as SEQ ID NO.1. The protein has the activity of combining aeromonas hydrophila, escherichia coli and staphylococcus aureus, and can effectively inhibit the growth of the microorganisms. The recombinant protein rEsKPI-1 shows an important application prospect in the fields of research and development of novel antibacterial immune preparations, aquatic feed additives and the like.

The invention relates to a gene of a humpback perch interferon regulatory factor IRF1 and application of the gene as an immunologic adjuvant, and belongs to the field of molecular biology technology and application, the sequence of the humpback perch IRF1 gene is as shown in SEQ ID NO.1, and the amino acid sequence of protein coded by the gene is as shown in SEQ ID NO.2. The eukaryotic expression plasmid of the humpback perch IRF1 constructed by the invention can be used as an immunologic adjuvant of the DNA vaccine pCTssj to improve the immune effect of the humpback perch IRF1 against vibrio harveyi infection, can be developed into an immune preparation, and has good practical application value.

The application discloses application of an immunological preparation in promoting cell immunogenic death and belongs to the technical field of cell immunity. The immunological preparation comprises a liposome delivery system; the liposome delivery system comprises ionizable phospholipids, double decyl dimethyl ammonium bromide, cholesterol and dimyristyl glycerol-polyethylene glycol 2000; and the molar proportion of the ionizable phospholipids in the liposome delivery system is 10-69%. Unlike traditional strategies for inducing cell immunogenic death, the application starts from the liposome, and the outstanding effects of the immunological preparation in inducing cell immunogenic death and promoting immune activation are verified through cell and animal experiments.

The invention relates to a dendritic cell capable of generating a T cell adapter, a preparation method and application of the dendritic cell, and an immune preparation containing the dendritic cell. The preparation method comprises the following steps: preparing a nucleic acid construct for coding a multispecific T cell adapter, the multispecific T cell adapter comprising a first antigen binding domain for specifically binding to CD3 on the surface of a T cell to activate the T cell, and a second antigen binding domain for specifically binding to NKG2DL on the surface of a tumor cell, and an immunomodulatory molecule interleukin-2, i.e., a third binding domain, capable of binding to an IL-2 receptor on the surface of an immune cell; and transferring the nucleic acid construct as an exogenous nucleic acid into the DC cell to obtain the dendritic cell for generating the T cell adapter. The dendritic cell for generating the T cell adapter can assist a human immune system in better and more targeted killing of tumor cells.